Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 1871Neoplasms 1257Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 802Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 449Ovarian Neoplasms 406Colonic Neoplasms 405Neoplasm Metastasis 403Uterine Cervical Neoplasms 400Recurrence 382Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Multiple Primary Lung Cancers × Clear all
NCT04982900 2021-10-05

TERMGGO

Ruijin Hospital

Phase 2 Unknown
138 enrolled
Thoracic

Multiple Primary Lung Cancers

NCT04026841 2019-08-02

The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Unknown
36 enrolled
Thoracic

Multiple Primary Lung Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡